<div id="readability-page-1"><p>Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 23,410,000 shares,  a growth of 29.6% from the November 15th total of 18,060,000 shares. Currently, 1.9% of the company's stock are sold short. Based on an average daily trading volume, of 6,840,000 shares, the short-interest ratio is presently 3.4 days.</p><div><p><span></span><span>Get <strong>Gilead Sciences</strong> alerts:</span></p></div><h2>Insider Buying and Selling</h2><ul><li>Gilead’s Stock Surge: What’s Fueling the Momentum?</li></ul><p>In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 447,234 shares of company stock valued at $41,288,086 over the last 90 days. Corporate insiders own  0.16% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently modified their holdings of the stock. Exome Asset Management LLC acquired a new position in shares of  Gilead Sciences during the 3rd quarter worth about $4,192,000.  Brass Tax Wealth Management Inc. acquired a new position in shares of  Gilead Sciences during the 3rd quarter worth about $242,000.  Garden State Investment Advisory Services LLC acquired a new position in shares of  Gilead Sciences during the 3rd quarter worth about $221,000.  Franklin Resources Inc. raised its position in shares of  Gilead Sciences by 22.8% during the 3rd quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company's stock worth $190,611,000 after purchasing an additional 416,379 shares during the last quarter.  Finally, Tri Ri Asset Management Corp acquired a new stake in  Gilead Sciences in the 3rd quarter valued at about $3,380,000. Institutional investors and hedge funds own  83.67% of the company's stock. </p><h2>Gilead Sciences Price Performance</h2><ul><li>Biotech Boom Ahead? Key Stocks and ETFs to Watch Now</li></ul><p>Shares of Gilead Sciences stock traded up $0.24 during trading hours on Friday, reaching $91.86. The stock had a trading volume of 7,515,462 shares, compared to its average volume of 7,068,425. The stock's 50 day moving average is $89.96 and its 200 day moving average is $79.55. The firm has a market capitalization of $114.48 billion, a PE ratio of 1,020.61, a PEG ratio of 2.38 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. </p><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.29 earnings per share.  Equities analysts expect that  Gilead Sciences will post 4.35 earnings per share for the current fiscal year. </p><h2>Gilead Sciences Dividend Announcement</h2><ul><li>Positive News is Driving This Cancer Drug Maker’s Stock Higher</li></ul><p>The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts have recently issued reports on GILD shares. Sanford C. Bernstein started coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an &#34;outperform&#34; rating and a $105.00 price target on the stock. Piper Sandler upped their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, November 7th. Robert W. Baird upped their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 7th. Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Finally, Leerink Partners raised Gilead Sciences from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their price target for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Twelve analysts have rated the stock with a hold rating, twelve have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $96.43.</p><p><b>Get Our Latest Analysis on GILD</b></p><h2>About Gilead Sciences</h2> (Get Free Report)<p>Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Gilead Sciences</li><li>High Dividend REITs: Are They an Ideal Way to Diversify?</li><li>Dave &amp; Buster’s: Is It Time to Make Another Play on This Stock?</li><li>Quiet Period Expirations Explained</li><li>Why Hershey Stock Has More Room to Run Despite Takeover Rejection</li><li>What Are Treasury Bonds?</li><li>Texas Instruments: The Old-School Tech Titan Still Delivering</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ BITCOIN <span><span>(From Awesomely, LLC)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg3NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg3NQ"/></p><h2>Should you invest $1,000 in Gilead Sciences right now?</h2><p>Before you consider Gilead Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p><p>While Gilead Sciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GILD

<p>Gilead Sciences, Inc. (NASDAQ:GILD) experienced a significant increase in short interest, rising 29.6% to 23,410,000 shares as of November 30. This represents 1.9% of the company's stock sold short, with a days-to-cover ratio of 3.4 days. Additionally, corporate insiders sold 447,234 shares over the last 90 days. Gilead's stock price reached $76.24, with a market cap of $48 billion and a PE ratio of 1,020.61. The company also declared a quarterly dividend of $0.77 per share, payable on December 30.</p>

Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Increase in Short Interest